Changes of Plasma Adiponectin Levels after Smoking Cessation

Wang-Youn Won, Chang-Uk Lee, Jeong-Ho Chae, Jung-Jin Kim, Chul Lee, and Dai-Jin Kim

Department of Psychiatry, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea

INTRODUCTION

Cigarette smoking is associated with a variety of health problems including cardiovascular, pulmonary, neoplasms, endocrinopathies including diabetes, the metabolic syndrome, and chronic inflammation. Adiponectin is an adipocyte-derived plasma protein that is closely associated with insulin sensitivity and the metabolic syndrome. The aim of this study was to evaluate the changes of plasma adiponectin levels after smoking cessation.

METHODS

Thirty seven smokers that wanted to stop smoking without any nicotine replacement therapy or medication were recruited for this study. Fifteen smokers succeeded in stopping smoking (validated by urine cotinine levels ≤50 ng/mL) and 22 smokers failed. Therefore, only the 15 that succeeded were included in the analysis. The plasma adiponectin levels were determined using a commercially available enzyme-linked immunosorbent assay.

RESULTS

The mean age of the successful 15 was 35±9.3 years old. They were all males. The daily smoking habit was a mean of 13.5±5.4 cigarettes per day. The mean Nicotine Dependence Syndrome Scale (NDSS) and Fagerstrom Test for Nicotine Dependence (FTND) scores were 55.6±9.6 and 2.9±1.9. During the study period of three months, the mean body mass index (BMI), body fat mass (BFM), waist-hip ratio (WHR) and body weight increased by 1.1 kg/m², 3.0%, 0.02%, and 2.9 kg, respectively. The baseline mean adiponectin level in the subjects was 11.9±5.2 mg/L. The mean adiponectin levels measured at one and three months were 16.0±5.1 mg/L and 14.7±4.5 mg/L respectively. The mean plasma adiponectin levels of the successful group was significantly increased after four weeks when compared to the baseline (z=-2.401, p=0.016). However, the decrease in plasma adiponectin levels at one and three months was not statistically significant.

CONCLUSION

Even though the decrease over the next two months was not significant, these findings, the increase of plasma level of adiponectin after smoking cessation, provide preliminary data for future research on the possible mechanisms associated with smoking cessation and changes in body metabolism.

Key Words Smoking cessation, Nicotine, Tobacco, Adiponectin, Ghrelin, Leptin, Metabolism.
of previous researches were designed as cross-sectional and used nicotine replacement therapy or medications. The aim of this study was to evaluate the changes of plasma adiponectin levels after smoking cessation. The subjects received no nicotine replacement therapy or medications (e.g., varenicline and bupropion). Moreover, the level of ghrelin and leptin, which have been associated with body weight and metabolism were assessed to determine their relationship to smoking cessation.

METHODS

Thirty seven smokers that wanted to quit smoking were recruited from the Bucheon St. Mary’s Hospital, the Catholic University of Korea. All subjects fulfilled the DSM-IV diagnostic criteria for the current diagnosis of nicotine dependence. The DSM-IV diagnoses were determined in a consensus with two board certificated psychiatrists using all available clinical instruments, including a semi-structured interview based on the DSM-IV criteria. The demographic data was collected at baseline. The levels of nicotine dependence were assessed using the Korean version of the Nicotine Dependence Syndrome Scale (NDSS) and the Fagerstrom Test for Nicotine Dependence (FTND). The exclusion criteria included current or past history of comorbid psychiatric illness, any neurological disorder, significant medical conditions, abnormal results on laboratory screening tests, addiction to alcohol or substances other than nicotine, and a history of head trauma accompanied by a loss of consciousness. All the participants agreed to quit smoking without any nicotine replacement therapy or nicotine-related medications, and to participate in a urine cotinine monitoring schedule over three months.

During the study period, smoking cessation was evaluated by both a self-report questionnaire and urine cotinine levels. The urine cotinine levels of all subjects were monitored at baseline and after 3 months. Urinary samples were taken without prior notification. The urine specimens were collected in a plastic container and stored at 4°C. The assay was performed on the day the sample was collected. Cotinine was analyzed using the Cotinine Enzyme Immunoassay on a 502X Multiple Chemistry Unit automated analyzer. The assay procedures and quality control were carried out according to the manufacturer’s instructions. Briefly, 35 μL of urine or calibrator was added in 125 μL of reagent including cotinine specific monoclonal antibodies and enzyme substrate. Then, 125 μL of cotinine labeled enzyme, and glucose-6-phosphate dehydrogenase was dispensed and incubated at 37°C. Spectrophotometric measurement was performed at 340 nm. Among the 37 participants, 15 smokers succeeded in quitting smoking (validated by urine cotinine level ≤50 ng/mL) and 22 smokers failed. Therefore, the 15 successful participants were included in the analysis.

The purpose and entire protocol of the study were explained to all subjects. All subjects provided written informed consent. The study protocol was approved by the hospital ethics committee of the Bucheon St. Mary’s Hospital, the Catholic University of Korea. All the procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983.

Body composition was analyzed using the Inbody 720 (Bio-space CO., Ltd., Seoul, Korea). All body composition parameters such as body mass index (BMI), body fat mass (BFM) and waist hip ratio (WHR) at baseline and after abstinence were included in the analysis.

Blood samples for routine blood chemistry were obtained from the participants four times: at baseline, and after 1, 2, and 3 months. Blood was drawn from all subjects at 7:00 a.m. after an overnight fasting.

The plasma adiponectin levels were checked at baseline, 1, and 3 months after smoking cessation. The plasma adiponectin levels were determined by using a commercially available enzyme-linked immunosorbent assay (Human Adipokine Panel A Multiplex Immunoassay Kit - ONE PLEX cat No. HADK1-61K-A01). The plasma leptin levels were determined using a radioimmunoassay (Linco Research, St. Charles, MO, USA) that utilizes 125I-labeled bioactive human leptin as a tracer as well as a rabbit polyclonal antibody against human leptin. The plasma ghrelin levels were measured using a commercially available RIA kit (Phoenix Pharmaceuticals, Inc., Belmont, CA, USA) that utilizes 125I-labeled bioactive ghrelin as a tracer and a rabbit polyclonal antibody against the full-length octanoylated human ghrelin.

The Kolmogorov-Smirnov test did not show a normal distribution of the data. Therefore, non-parametric tests were used to evaluate statistical significance. A Wilcoxon signed rank test was used to analyze the differences in baseline and at each point in time that the plasma adiponectin levels were obtained in the subjects. The Spearman’s correlation test was carried out to analyze the correlation between the plasma levels of adiponectin and the levels of ghrelin, leptin or other variables. All of the statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS) version 12.0 for Windows. The level of statistical significance was set at p<0.05. All data are presented as the mean±standard deviation (SD).

RESULTS

The demographic data at baseline were as follows: the mean age of the successful 15 was 34±8.4 years of aged. They were all males. The daily cigarettes (cigarettes/day) smoked were 12.9±5.3. The mean NDSS and FTND scores were 55.9±9.2 and 2.8±1.9.

All of the body composition parameters such as BMI, BFM,
WHR and weight were higher in the 15 subjects after 3-months of abstinence when compared to the baseline (Table 1). After the 3 month period of smoking cessation, the mean BMI, BFM, WHR and body weight increased by 1.1 kg/m², 3.0%, 0.02%, and 2.9 kg, respectively.

Figure 1 shows the plasma adiponectin levels at each point in time for the 15 successful participants. The baseline adiponectin level was 11.9±5.2 mg/L. The mean adiponectin levels measured at 1 month and 3 months were 16.0±5.1 mg/L and 14.7±4.5 mg/L. The mean plasma adiponectin levels of the quitters were significantly increased after 4 weeks when compared to baseline (z=-2.401, p=0.016). However, the decrease in plasma adiponectin level between month 1 and month 3 was not statistically significant (z=-0.801, p=0.423).

The plasma level of leptin increased and level of ghrelin decreased after smoking cessation although the changes of variables are not significant. There was no significant correlation between adiponectin and ghrelin or leptin, and the body composition indices analyzed. Regarding the lipid profiles including total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride, all the variables increased after 4 weeks of smoking cessation.

DISCUSSION

The results of this study demonstrated that smoking cessation was significantly associated with increased plasma adiponectin levels. There are several reports with similar findings. Iwashima et al. and Takefuji et al. reported the association between smoking status and the plasma level of adiponectin. They showed that cigarette smoking correlated with low plasma adiponectin levels. In addition, a dose-dependent associa-

| Table 1. Demographic data and comparison of variables at each point in time |
|-------------------------------------------------|
| Month | 0 | 1 | 3 |
|---|---|---|---|
| Appetite (a) (VAS/cm) | 4.8±1.6 | 5.6±1.9 | 6.2±1.4* |
| Appetite (b) (VAS/cm) | 4.1±2.5 | 4.3±2.3 | 4.9±1.9* |
| Weight (kg) | 73.2±8.1 | 74.2±7.6 | 75.1±8.6* |
| BMI (kg/m²) | 24.4±2.9 | 24.9±2.7 | 25.1±3.2* |
| Adiponectin (mg/L) | 11.9±5.2 | 16.0±5.1* | 14.7±4.5 |
| Leptin (ng/mL) | 4.8±1.1 | 6.5±1.9 | 7.6±2.3 |
| Ghrelin (pg/mL) | 129.2±23.6 | 85.6±19.4 | 71.3±10.5 |
| GOT (AST) (U/L) | 28.9±9.8 | 31.4±11.6 | 36.9±16.0 |
| GPT (ALT) (U/L) | 35.5±23.8 | 38.9±30.2 | 47.1±35.3 |
| Glucose (mg/dL) | 86.7±9.1 | 86.5±10.2 | 90.1±6.2 |
| Creatinine (mg/dL) | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 |
| Uric acid (mg/dL) | 5.6±1.1 | 6.0±1.2 | 5.8±1.5 |
| Total cholesterol (mg/dL) | 182.8±33.3 | 194.1±36.9 | 180.0±32.1 |
| HDL-cholesterol (mg/dL) | 54.8±10.0 | 56.9±10.4 | 53.1±11.1 |
| LDL-cholesterol (mg/dL) | 114.6±29.6 | 120.2±30.1 | 108.6±27.7 |
| Triglyceride (mg/dL) | 111.7±81.1 | 126.4±102.5 | 150.9±93.6 |
| Insulin (mcU/mL) | 6.6±6.0 | 9.7±8.5 | 7.2±4.0 |
| WBC (10³/L) | 6.9±1.1 | 7.1±1.4 | 7.0±1.0 |
| RBC (10¹²/L) | 5.2±0.4 | 5.2±0.4 | 5.2±0.4 |
| Hemoglobin (g/dL) | 15.7±1.2 | 15.9±1.3 | 15.8±1.2 |
| Hematocrit (%) | 47.1±3.3 | 47.1±3.5 | 46.9±2.9 |
| Platelet (10⁹/L) | 239±32.4 | 241.27±33.4 | 268.55±38.2 |
| MCV (fL) | 89.95±3.9 | 89.47±2.3 | 89.15±2.9 |
| MCH (pg) | 29.99±0.9 | 30.15±0.8 | 30.18±1.0 |
| MCHC (%) | 33.36±1.0 | 33.72±0.7 | 33.86±1.0* |

*statistical significance between baseline and endpoint (p<0.05). BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, HDL-cholesterol: high-density lipoprotein cholesterol, LDL-cholesterol: low-density lipoprotein cholesterol, WBC: white blood cell, RBC: red blood cell, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration
metabolism. Systemic adiponectin resulted in increased thermogenesis, weight loss and reduction in serum glucose and lipid levels. Adiponectin has unique central actions, which all play a role in body metabolism and fat distribution. Even though medication effects associated with nicotine replacement therapy or nicotine-related medications including varenicline or bupropion were used for smoking cessation in this study.

Adiponectin is known to improve insulin sensitivity and the lipid profile by stimulation of adenosine monophosphate-activated protein kinase in skeletal muscle cells and the liver. By contrast, insulin resistance which is related to low plasma levels of adiponectin, lower HDL-C concentration and by decreasing VLDL-C production, as well as by increasing the expression of lipoprotein lipase. Another example of the possible correlation between smoking and serum levels of adiponectin is the association between smoking intensity and plasma adiponectin levels. The mean plasma adiponectin levels were increased between baseline and 1 month (z=-2.401, p=0.016), but decreased from month 1 to 3 months (z=-0.801, p=0.423).

To our knowledge, although the above studies showed an association between smoking cessation and plasma adiponectin concentration and insulin resistance in Caucasian smokers, Patel et al. reported that circulating serum adiponectin levels in patients with coronary artery disease were related to the atherosclerotic burden or risk. Most of the studies on the association between plasma levels of adiponectin and smoking status were cross-sectional studies. Recent research reported by Efthathiou et al. showed that serum adiponectin levels appeared to increase significantly within 2 months after smoking cessation.

Figure 1. The box plots show the median and quartiles, and the whisker caps of the box plots show the mean 5th and 95th percentile values. *indicates statistical significance (p<0.05). A Wilcoxon signed rank test yielded the results. The plasma levels of adiponectin at baseline, 1 month, and 3 months were 11.9±5.2, 16.0±5.1, and 14.7±4.5 mg/L, respectively. The mean plasma adiponectin levels were increased between baseline and 1 month (z=-2.401, p=0.016), but decreased from month 1 to 3 months (z=-0.801, p=0.423).

Recently, adiponectin has been reported to generate a negative energy balance by increasing energy expenditure. In contrast to leptin, intracerebroventricular administration of adiponectin decreased body weight mainly by stimulating energy expenditure. Systemic adiponectin resulted in increased thermogenesis, weight loss and reduction in serum glucose and lipid levels. Adiponectin also potentiated the effect of leptin on thermogenesis and lipid levels. Adiponectin has unique central effects on energy homeostasis based on these findings. Spranger et al. reported that the identification of adiponectin receptors on brain endothelial cells and the finding of a modified secretion pattern of centrally active substances in blood-brain barrier (BBB) cells provides an alternate explanation of how adiponectin effects energy metabolism. In addition, Kubota et al. suggested that energy homeostasis may be mediated by both short-term regulators, such as gut hormones, and long-term regulators including adiponectin that allow energy to be stored efficiently. These findings offer an insight into adiponectin’s influence on the central nervous system as well as the peripheral nervous system.

The evidence suggests that there is an association between the body’s energy metabolism, weight change, body composition, appetite-controlling gut hormones (ghrelin or leptin), and adiponectin, which all play a role in body metabolism and fat distribution. Even though medication effects associated with
smoking cessation were excluded in this study, there were no correlations observed among the study variables. However, the plasma level of adiponectin increased within 4 weeks of smoking cessation and there was a decrease during the next 2 months, which was not statistically significant. This result may be due to another as yet to be identified mechanism associated with energy metabolism or due to one of the several limitations of this study.

The main limitation of this study was the small sample size, which did not have the statistical power to show serial changes in the plasma levels of adiponectin. The subjects that succeeded and were included in the analysis had lower FTND scores than the participants that could not be abstinent during the study period. If the heavy smokers were included, the results might have had a greater statistical power. The reasons of low FTND scores of participants and the low proportion of successful quitters (15 of 37) were because this study did not include using any nicotine replacement therapy, so the heavy smokers were not included in the analysis.

Another limitations are that plasma adiponectin levels of non quitters were not measured and the levels of smoking quitters after 2 months not checked in this study. Also, there are numbers of confounding factors affecting the adiponectin level.

In summary, although there are several limitations in the current study, the results of this study showed that the plasma level of adiponectin increased after a short period (4 weeks) of smoking cessation. Even though there was a decrease during the next 2 months, the difference was not statistically significant. These findings provide preliminary results for future research on the possible mechanisms associated with smoking cessation and the related changes in metabolism.

Acknowledgments

This study was supported by a grant of the Ministry of education, science and technology, 2009, Republic of Korea.

REFERENCES

1. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General, Rockville: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004.

2. Beltowski J, Jamroz-Wisienewska A, Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008;8:7-46.

3. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.

4. Havel PJ. Control of energy homeostasis and insulin action by adipocytokines: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51-59.

5. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89.

6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-1737.

7. Miyazaki T, Shimada K, Mokuno H, Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart 2003;89:663.

8. Thamer C, Stefan N, Stumvoll M, Hirng H, Fritsche A. Reduced adiponectin serum levels in smokers. Atherosclerosis 2005;179:421-422.

9. Efthathiou SP, Skeva I, Dimas C, Panagiotou A, Paris K, Tsanoumis L, et al. Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population. Atherosclerosis 2009;205:632-636.

10. Takefuji S, Yatsuhi H, Tamakoshi K, Otsuka R, Wada K, Matsushita K, et al. Smoking status and adiponectin in healthy Japanese men and women. Prev Med 2007;45:471-475.

11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.

12. Heatherton TF, Kozlowsky LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 1991;86:1119-1127.

13. Ishikawa K, Katsuya T, Murakami S, Ohishi M, Morio T, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005;45:1094-1100.

14. Abbasi F, Farin HM, Lamendola C, McLaughlin T, Schwartz EA, Reaven GM, et al. The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. J Clin Endocrinol Metab 2006;91:5002-5007.

15. Patel IV, Abraheim A, Dotsenko O, Creamer J, Gunning M, Hughes EA, et al. Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function. J Intern Med 2008;264:593-598.

16. Croen M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-469.

17. Staiger H, Tichrutter O, Machann J, Thamer C, Fritsche A, Maerker E, et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003;11:368-372.

18. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res 2005;13:1466-1475.

19. Bania C, Trichopoulou A, Lenas D, Trichopoulos D. Tobacco smoking in relation to body fat mass and distribution in a general population sample. Int J Obes Relat Metab Disord 2004;28:1091-1096.

20. Dallosso HM, James WP. The role of smoking in the regulation of energy balance. Int J Obes 1984;8:365-375.

21. Ferrara CM, Kumar M, Nicklas B, McCrone S, Goldberg AP. Weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes Relat Metab Disord 2004;28:1091-1096.

22. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. Obes Rev 2004;5:95-103.

23. Moffatt RJ, Owens SG. Cessation from cigarette smoking: changes in lipid metabolism and weight gain. Obes Rev 2004;5:95-103.

24. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes Relat Metab Disord 2004;28:1091-1096.

25. Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res 2005;13:1466-1475.

26. Ferrara CM, Kumar M, Nicklas B, McCrone S, Goldberg AP. Weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes Relat Metab Disord 2004;28:1091-1096.

27. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. Obes Rev 2004;5:95-103.

28. Moffatt RJ, Owens SG. Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption. Metabolism 1991;40:465-470.

29. Stanford BA, Matter O, Feller RD, Papanek P. Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids. Am J Clin Nutr 1986;43:486-494.

30. Harvey J. Leptin regulation of neuronal excitability and cognitive function. Curr Opin Pharmacol 2007;7:643-647.

31. van der Lely AJ, Tschp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-457.

32. Lee H, Joe KH, Kim W, Park J, Lee DH, Sung KW, et al. Increased leptin and decreased ghrelin level after smoking cessation. Neurosci Lett 2006;409:47-51.

33. Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Schildle AL, et al.
Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006;55:141-147.

29. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Payvani UB, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-529.

30. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007;6:55-68.